Todd Bauer on Muck Rack

Todd Bauer

As seen in: Nature, The Oncologist, The New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, Texas Medical Center, Future Medicine, ONCOLOGY journal, EMJ- European Medical Journal, Targeted Oncology and

Get in touch with Todd

Contact Todd, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

ERK plays a conserved dominant role in pancreas cancer cell EMT heterogeneity driven by diverse growth factors and chemotherapies

|
By Michelle Barbeau, Brooke Brown, Sara J. Adair, Todd Bauer
| biorxiv.org
Abstract Epithelial-mesenchymal transition (EMT) occurs heterogeneously among malignant carcinoma cells to promote chemoresistance. Identifying the signaling pathways involved will nominate drug combinations to promote chemoresponse, but cell population-level studies are inherently fraught, and single-cell transcriptomics are limited to indirect ontology-based inferences.
Open in Who Shared Issue with article?

Assessing Treatment Options for ALK+ NSCLC

|
By Todd Bauer, Sandip Patel, Jonathan W. Riess, Mary Grizzard, Kasey Bamel, Cindy Ludovico
| ONCOLOGY journal Verified
January 31, 2025 By This video segment provides an in-depth discussion on the first-line use of lorlatinib for ALK-positive metastatic NSCLC, including clinical evidence from the phase 3 CROWN trial, the broader therapeutic landscape and alternative strategies, real-world insights on lorlatinib's performance, and key considerations for selecting among ALK inhibitors based on patient-specific factors.
Open in Who Shared Issue with article?

The Benefits of Lorlatinib for ALK+ NSCLC: CROWN Update

|
By Todd Bauer, Sandip Patel, Jonathan W. Riess, Mary Grizzard, Kasey Bamel, Cindy Ludovico
| ONCOLOGY journal Verified
January 31, 2025 By This video segment reviews the clinical evidence supporting lorlatinib as a first-line treatment for ALK-positive metastatic NSCLC, emphasizing key efficacy outcomes from the phase 3 CROWN trial. Video content above is prompted by the following: Can you summarize the clinical evidence supporting lorlatinib use in the first-line treatment of ALK+ metastatic NSCLC? Could you highlight the primary efficacy outcomes from the phase 3 CROWN trial? Related Content Related Content
Open in Who Shared Issue with article?
See all 26 licensed articles (34 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified